NCT05699213 MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening
| NCT ID | NCT05699213 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cedars-Sinai Medical Center |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-06-27 |
| Primary Completion | 2026-06-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-06-27 with a primary completion date of 2026-06-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this pilot observational study is to evaluate the accrual and retention rate of a study population from a centralized lung cancer screening program to support MRI and blood-based biomarker research for lung cancer screening.
Eligibility Criteria
Inclusion Criteria: * Ability to read and understand informed consent * Male or female adults who are at high risk for lung cancer and are enrolled in the centralized lung cancer screening program: Based on USPSTF guidelines: Age 50-80 with 20 or greater pack-year smoking story who continue to smoke or quit within the past 15 years without sign or symptoms of lung cancer. Or based on National Comprehensive Cancer Network (NCCN) guidelines but do not meet the USPSTF guidelines, age 50-unlimited * Found to have one or more lung nodules that is 6mm or greater on screening LDCT Exclusion Criteria: * Persons with an active diagnosis of cancer * Persons with active signs or symptoms of lung cancer * Persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps. * Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged. * Persons who are pregnant, nursing, are implanted with intrauterine devices (IUD's) that are not MR-compatible * Persons unable to tolerate MRI imaging secondary to an inability to lie supine or severe claustrophobia. * Persons who are non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions
Contact & Investigator
Sara Ghandehari, MD
PRINCIPAL INVESTIGATOR
Cedars-Sinai
Frequently Asked Questions
Who can join the NCT05699213 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05699213 currently recruiting?
Yes, NCT05699213 is actively recruiting participants. Contact the research team at weijia.chua@cshs.org for enrollment information.
Where is the NCT05699213 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT05699213 clinical trial?
NCT05699213 is sponsored by Cedars-Sinai Medical Center. The principal investigator is Sara Ghandehari, MD at Cedars-Sinai. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.